Biogen Stock Price, News & Analysis (NASDAQ:BIIB)

$344.44 -0.43 (-0.12 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$344.44
Today's Range$337.50 - $345.00
52-Week Range$244.28 - $348.84
Volume1.29 million shs
Average Volume1.22 million shs
Market Capitalization$72.84 billion
P/E Ratio21.12
Dividend YieldN/A
Beta0.73

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone+1-781-4642000

Debt

Debt-to-Equity Ratio0.46%
Current Ratio2.19%
Quick Ratio1.90%

Price-To-Earnings

Trailing P/E Ratio21.1183323114654
Forward P/E Ratio15.66
P/E Growth1.92

Sales & Book Value

Annual Sales$11.45 billion
Price / Sales6.36
Cash Flow$24.04 per share
Price / Cash14.33
Book Value$56.18 per share
Price / Book6.13

Profitability

Trailing EPS$16.31
Net Income$3.70 billion
Net Margins29.44%
Return on Equity38.51%
Return on Assets20.80%

Miscellaneous

Employees7,400
Outstanding Shares211,480,000

Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, October, 24th. The biotechnology company reported $6.31 earnings per share for the quarter, beating the Zacks' consensus estimate of $5.70 by $0.61. The biotechnology company earned $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. Biogen's quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $5.19 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Biogen.

Where is Biogen's stock going? Where will Biogen's stock price be in 2018?

28 brokers have issued 1 year price targets for Biogen's stock. Their predictions range from $279.00 to $420.00. On average, they expect Biogen's stock price to reach $355.33 in the next twelve months. View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Mizuho analysts commented, "We have included our key takeaways below. We also had the chance to catch up with management after the event to get additional color. Our key takeaways from both are below." (1/5/2018)
  • 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
  • 3. Citigroup Inc analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
  • 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 5. Cowen Inc analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board (Age 68)
  • Michel Vounatsos, Chief Executive Officer, Director (Age 55)
  • Jeffrey D. Capello, Chief Financial Officer, Executive Vice President (Age 53)
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President (Age 49)
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources (Age 58)
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary (Age 60)
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development (Age 48)
  • Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs (Age 54)
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations (Age 51)

Who owns Biogen stock?

Biogen's stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.39%), Waverton Investment Management Ltd (0.14%), Bank of Montreal Can (0.12%), Factory Mutual Insurance Co. (0.09%), National Pension Service (0.08%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, AMI Asset Management Corp, Montrusco Bolton Investments Inc., Livforsakringsbolaget Skandia Omsesidigt, Trust Department MB Financial Bank N A, Oakbrook Investments LLC and Boltwood Capital Management. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Bank of Montreal Can, Waverton Investment Management Ltd, First American Trust FSB, Broadleaf Partners LLC, Factory Mutual Insurance Co., Legacy Private Trust Co. and Country Trust Bank. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $344.44.

How big of a company is Biogen?

Biogen has a market capitalization of $72.84 billion and generates $11.45 billion in revenue each year. The biotechnology company earns $3.70 billion in net income (profit) each year or $16.31 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

How can I contact Biogen?

Biogen's mailing address is 225 Binney St, CAMBRIDGE, MA 02142-1031, United States. The biotechnology company can be reached via phone at +1-781-4642000.


MarketBeat Community Rating for Biogen (BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,212 (Vote Outperform)
Underperform Votes:  715 (Vote Underperform)
Total Votes:  1,927
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biogen (NASDAQ:BIIB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.682.682.58
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
20 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $355.33$345.54$342.83$327.76
Price Target Upside: 4.86% upside5.37% upside0.48% downside15.96% upside

Biogen (NASDAQ:BIIB) Consensus Price Target History

Price Target History for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Canaccord GenuitySet Price TargetHold -> Hold$340.00 -> $350.00HighView Rating Details
1/16/2018CitigroupReiterated RatingOutperform$350.00 -> $380.00MediumView Rating Details
1/15/2018OppenheimerSet Price TargetBuy$380.00MediumView Rating Details
1/5/2018MizuhoSet Price TargetBuy$400.00HighView Rating Details
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHighView Rating Details
12/30/2017NomuraBoost Price TargetBuy$355.00 -> $420.00N/AView Rating Details
12/20/2017Credit Suisse GroupUpgradeNeutral -> Outperform$321.00 -> $385.00LowView Rating Details
12/5/2017Royal Bank of CanadaReiterated RatingHold$321.00LowView Rating Details
11/27/2017CowenReiterated RatingBuy$338.00LowView Rating Details
11/27/2017BMO Capital MarketsReiterated RatingBuy$385.00LowView Rating Details
11/27/2017JPMorgan Chase & Co.Set Price TargetBuy$378.00MediumView Rating Details
11/28/2017Sanford C. BernsteinSet Price TargetBuy$310.00 -> $318.00MediumView Rating Details
10/25/2017HC WainwrightReiterated RatingBuy$340.00N/AView Rating Details
10/24/2017SunTrust BanksReiterated RatingBuy$354.00N/AView Rating Details
10/24/2017Cantor FitzgeraldReiterated RatingHold$279.00N/AView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$402.00N/AView Rating Details
10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
9/21/2017Raymond James FinancialDowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
8/25/2017Robert W. BairdReiterated RatingHold$290.00LowView Rating Details
8/16/2017Goldman Sachs GroupUpgradeBuy -> Conviction-Buy$338.00LowView Rating Details
7/26/2017Deutsche BankReiterated RatingBuy$315.00 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
7/11/2017Jefferies GroupReiterated RatingHold -> Hold$310.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
4/23/2017BarclaysReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Biogen (NASDAQ:BIIB) Earnings History and Estimates Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018$5.54N/AView Earnings Details
10/24/2017Q3 2017$5.70$6.31$3.05 billion$3.08 billionViewN/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
10/26/2010Q3 2010$1.20$1.33ViewN/AView Earnings Details
7/20/2010Q2 2010$1.08$1.28ViewN/AView Earnings Details
4/20/2010Q1 2010$1.12$1.05ViewN/AView Earnings Details
2/9/2010Q4 2009$1.05$1.17ViewN/AView Earnings Details
10/20/2009Q3 2009$1.02$1.09ViewN/AView Earnings Details
7/16/2009Q2 2009$0.89$0.73ViewN/AView Earnings Details
4/16/2009Q1 2009$1.00$1.05ViewN/AView Earnings Details
2/6/2009Q4 2008$0.88$0.91ViewN/AView Earnings Details
10/21/2008Q3 2008$0.89$0.95ViewN/AView Earnings Details
7/22/2008Q2 2008$0.83$0.91ViewN/AView Earnings Details
4/23/2008Q1 2008$0.78$0.82ViewN/AView Earnings Details
2/6/2008Q4 2007$0.79$0.89ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Biogen (NASDAQ:BIIB) Earnings Estimates

2018 EPS Consensus Estimate: $24.34
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$5.62$6.08$5.86
Q2 20184$5.93$6.35$6.14
Q3 20184$6.04$6.24$6.18
Q4 20183$6.12$6.23$6.17
Q1 20191$6.30$6.30$6.30
Q2 20191$6.53$6.53$6.53
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.14%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Biogen (NASDAQ BIIB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Michel VounatsosCEOBuy780$320.55$250,029.004,879View SEC Filing  
1/9/2018Robert W PangiaDirectorSell5,832$329.65$1,922,518.8023,539View SEC Filing  
12/29/2017Michel VounatsosCEOBuy780$320.55$250,029.00View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy30,000$317.36$9,520,800.0010,029View SEC Filing  
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.7422,258View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.0027,232View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.046,330View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.0010,813View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.487,060View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.0520,705View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.5022,078View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.287,579View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.007,172View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.0019,663View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.0054,779View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.002,402View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.0054,936View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.7056,265View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.0059,633View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.3859,790View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.001,848View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.0060,277View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.2160,434View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.1960,921View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.608,127View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.707,990View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.527,990View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.9259,848View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.087,740View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.007,740View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.007,890View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.155,749View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.8824,019View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.006,970View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.6626,142View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.0014,003View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.006,435View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.0014,468View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.457,976View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.438,191View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.243,511View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.1854,389View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.1621,407View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.809,412View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.3513,667View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.3652,961View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.8010,440View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.003,325View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.0018,509View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.5014,003View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.003,325View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.008,710View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.007,087View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.984,885View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.107,087View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.008,710View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.6043,522View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.804,571View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biogen (NASDAQ BIIB) News Headlines

Source:
DateHeadline
Stocks With Rising Relative Strength: BiogenStocks With Rising Relative Strength: Biogen
finance.yahoo.com - January 18 at 3:20 PM
Oppenheimer Equities Analysts Raise Earnings Estimates for Biogen Inc (BIIB)Oppenheimer Equities Analysts Raise Earnings Estimates for Biogen Inc (BIIB)
www.americanbankingnews.com - January 18 at 7:20 AM
Biogen (BIIB) Scheduled to Post Earnings on ThursdayBiogen (BIIB) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - January 18 at 2:50 AM
Notable Wednesday Option Activity: PSX, BIIB, JCINotable Wednesday Option Activity: PSX, BIIB, JCI
www.nasdaq.com - January 17 at 3:19 PM
Q1 2018 Earnings Estimate for Biogen Inc Issued By Oppenheimer (BIIB)Q1 2018 Earnings Estimate for Biogen Inc Issued By Oppenheimer (BIIB)
www.americanbankingnews.com - January 17 at 12:34 PM
Biogen Inc (BIIB) Expected to Announce Quarterly Sales of $3.06 BillionBiogen Inc (BIIB) Expected to Announce Quarterly Sales of $3.06 Billion
www.americanbankingnews.com - January 15 at 2:04 AM
Robert W. Pangia Sells 5,832 Shares of Biogen Inc (BIIB) StockRobert W. Pangia Sells 5,832 Shares of Biogen Inc (BIIB) Stock
www.americanbankingnews.com - January 10 at 6:48 PM
How will tax reform affect Biogen? Its CFO offered a few hints at J.P. MorganHow will tax reform affect Biogen? Its CFO offered a few hints at J.P. Morgan
finance.yahoo.com - January 10 at 3:19 PM
Health-care ETF tumbles as biotechnology stocks weighHealth-care ETF tumbles as biotechnology stocks weigh
www.marketwatch.com - January 8 at 3:23 PM
Biogen (BIIB) Upgraded to Buy by BidaskClubBiogen (BIIB) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
Biogen (BIIB) PT Set at $400.00 by MizuhoBiogen (BIIB) PT Set at $400.00 by Mizuho
www.americanbankingnews.com - January 6 at 10:58 AM
Biogen (BIIB) Given a $340.00 Price Target by Canaccord Genuity AnalystsBiogen (BIIB) Given a $340.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - January 6 at 9:56 AM
Biogen Unlikely To See Spinraza Rival In 2018 As AveXis DelayedBiogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed
finance.yahoo.com - January 5 at 3:20 PM
Biogen Inc (BIIB) Given Average Recommendation of "Buy" by AnalystsBiogen Inc (BIIB) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 5 at 1:54 PM
Can Biogen, Ionis' Spinraza Keep Up With Expectations After Q4?Can Biogen, Ionis' Spinraza Keep Up With Expectations After Q4?
finance.yahoo.com - January 4 at 3:19 PM
Solid Biosciences on deck for IPO - Seeking AlphaSolid Biosciences on deck for IPO - Seeking Alpha
seekingalpha.com - January 2 at 8:22 PM
Biogen Inc (BIIB) CEO Michel Vounatsos Bought $250,029 of SharesBiogen Inc (BIIB) CEO Michel Vounatsos Bought $250,029 of Shares
finance.yahoo.com - January 2 at 8:22 PM
Insider Buying: Biogen Inc (BIIB) CEO Buys 780 Shares of StockInsider Buying: Biogen Inc (BIIB) CEO Buys 780 Shares of Stock
www.americanbankingnews.com - January 2 at 7:04 PM
Biogen Inc (BIIB) CEO Buys $250,029.00 in StockBiogen Inc (BIIB) CEO Buys $250,029.00 in Stock
www.americanbankingnews.com - January 2 at 7:04 PM
Biogen price hikes on multiple sclerosis drugs could provide lift into 18: RBCBiogen price hikes on multiple sclerosis drugs 'could provide lift into '18': RBC
finance.yahoo.com - January 2 at 3:20 PM
Biogen (BIIB) Given a $350.00 Price Target by Oppenheimer AnalystsBiogen (BIIB) Given a $350.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - December 31 at 1:32 PM
Biogen Inc (BIIB) Expected to Post Quarterly Sales of $3.05 BillionBiogen Inc (BIIB) Expected to Post Quarterly Sales of $3.05 Billion
www.americanbankingnews.com - December 30 at 4:08 PM
Biogen (BIIB) Given New $420.00 Price Target at NomuraBiogen (BIIB) Given New $420.00 Price Target at Nomura
www.americanbankingnews.com - December 30 at 8:44 AM
 Analysts Anticipate Biogen Inc (BIIB) Will Announce Earnings of $5.50 Per Share Analysts Anticipate Biogen Inc (BIIB) Will Announce Earnings of $5.50 Per Share
www.americanbankingnews.com - December 28 at 5:20 AM
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, SucampoBiotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
finance.yahoo.com - December 27 at 9:54 AM
BioMarin Pharmaceutical (BMRN) vs. Biogen (BIIB) Head-To-Head SurveyBioMarin Pharmaceutical (BMRN) vs. Biogen (BIIB) Head-To-Head Survey
www.americanbankingnews.com - December 26 at 7:20 AM
FY2017 Earnings Forecast for Biogen Inc (BIIB) Issued By Jefferies GroupFY2017 Earnings Forecast for Biogen Inc (BIIB) Issued By Jefferies Group
www.americanbankingnews.com - December 25 at 3:28 AM
Eisai, Biogen (BIIB) Say Phase II Study of BAN2401 Did not Meet Criteria for Success based on Bayesian Analysis at ... - StreetInsider.comEisai, Biogen (BIIB) Say Phase II Study of BAN2401 Did not Meet Criteria for Success based on Bayesian Analysis at ... - StreetInsider.com
www.streetinsider.com - December 23 at 3:30 PM
Nomura Raises Biogen (BIIB) Price Target to $420.00Nomura Raises Biogen (BIIB) Price Target to $420.00
www.americanbankingnews.com - December 22 at 10:56 AM
Q4 2017 EPS Estimates for Biogen Inc Lowered by Jefferies Group (BIIB)Q4 2017 EPS Estimates for Biogen Inc Lowered by Jefferies Group (BIIB)
www.americanbankingnews.com - December 22 at 9:22 AM
Notable Thursday Option Activity: KMX, BIIB, ALGNNotable Thursday Option Activity: KMX, BIIB, ALGN
www.nasdaq.com - December 21 at 3:18 PM
Biogens Alzheimers drug fails to meet main goal in mid-stage trialBiogen's Alzheimer's drug fails to meet main goal in mid-stage trial
finance.yahoo.com - December 21 at 3:18 PM
UPDATE: Biogen shares drop 3% on negative update for Alzheimers disease drugUPDATE: Biogen shares drop 3% on negative update for Alzheimer's disease drug
finance.yahoo.com - December 21 at 3:18 PM
Why the Latest Biogen Readout Could Be a Chance to Get In CheapWhy the Latest Biogen Readout Could Be a Chance to Get In Cheap
finance.yahoo.com - December 21 at 3:18 PM
Biogen Shares Drop After Alzheimer's Drug Misses In TestingBiogen Shares Drop After Alzheimer's Drug Misses In Testing
finance.yahoo.com - December 21 at 3:18 PM
Mizuho Analysts Give Biogen (BIIB) a $400.00 Price TargetMizuho Analysts Give Biogen (BIIB) a $400.00 Price Target
www.americanbankingnews.com - December 21 at 3:06 PM
Canaccord Genuity Analysts Give Biogen (BIIB) a $340.00 Price TargetCanaccord Genuity Analysts Give Biogen (BIIB) a $340.00 Price Target
www.americanbankingnews.com - December 21 at 9:36 AM
Biogen (BIIB) Lifted to Outperform at Credit Suisse GroupBiogen (BIIB) Lifted to Outperform at Credit Suisse Group
www.americanbankingnews.com - December 20 at 10:56 PM
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 20183 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018
finance.yahoo.com - December 20 at 3:18 PM
Biogens (BIIB) "Buy" Rating Reiterated at Piper Jaffray CompaniesBiogen's (BIIB) "Buy" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - December 18 at 1:36 PM
Biotech Celgene May Rise 35% In 2018Biotech Celgene May Rise 35% In 2018
finance.yahoo.com - December 15 at 3:19 PM
Biogen, Ionis Sink After Company Announces Rival To SpinrazaBiogen, Ionis Sink After Company Announces Rival To Spinraza
finance.yahoo.com - December 14 at 3:19 PM
 Brokerages Expect Biogen Inc (BIIB) Will Post Quarterly Sales of $3.05 Billion Brokerages Expect Biogen Inc (BIIB) Will Post Quarterly Sales of $3.05 Billion
www.americanbankingnews.com - December 12 at 2:52 AM
Biogen Inc (BIIB) Receives Consensus Rating of "Buy" from BrokeragesBiogen Inc (BIIB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 11 at 4:32 PM
Vapid Sales Growth Penalize Biogen (BIIB) RatingVapid Sales Growth Penalize Biogen (BIIB) Rating
investorplace.com - December 11 at 3:49 PM
Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : December 6, 2017
finance.yahoo.com - December 6 at 3:18 PM
Biogen vet launches cancer drug startup with $50M from GV, othersBiogen vet launches cancer drug startup with $50M from GV, others
finance.yahoo.com - December 6 at 6:46 AM
Biogen (BIIB) PT Set at $350.00 by OppenheimerBiogen (BIIB) PT Set at $350.00 by Oppenheimer
www.americanbankingnews.com - December 5 at 6:34 PM
ETFs with exposure to Biogen, Inc. : December 5, 2017ETFs with exposure to Biogen, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:19 PM
Biogen (BIIB) Price Target Raised to $321.00 at Royal Bank Of CanadaBiogen (BIIB) Price Target Raised to $321.00 at Royal Bank Of Canada
www.americanbankingnews.com - December 5 at 12:38 PM

SEC Filings

Biogen (NASDAQ:BIIB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biogen (NASDAQ BIIB) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.